Exchange: NASDAQ·Updated 12:04 PM EDT
LGVN logo

LGVN Longeveron Inc - Ordinary Shares - Class A

$0.6798
$0.158
(18.86%)
Today
Reported EarningsAug 12
Mkt Cap$26.71M
Vol900,651.00

About LGVN

Longeveron, Inc. is a clinical stage biotechnology company, which engages in the development of cellular therapies for specific aging-related and life-threatening conditions. Its lead product, LOMECEL-B, is a cell-based therapy product, which is derived from culture-expanded medicinal signaling cells that are sourced from bone marrow of young, healthy, adult donors. The company was founded by Joshua M. Hare and Donald M. Soffer on October 9, 2014 and is headquartered in Miami, FL.
74

Bullish Sentiment

How do you feel about LGVN?

Advertisement|Remove ads.